{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:16:20Z","timestamp":1788066980407,"version":"build-2784847793"},"reference-count":66,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T00:00:00Z","timestamp":1787875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Science Foundation","award":["#OIA-1655740"],"award-info":[{"award-number":["#OIA-1655740"]}]},{"award":["#OIA-1655740"],"award-info":[{"award-number":["#OIA-1655740"]}],"id":[{"id":"https:\/\/ror.org\/021nxhr62","id-type":"ROR","asserted-by":"publisher"}]},{"name":"NSF CAREER Award","award":["#2046694"],"award-info":[{"award-number":["#2046694"]}]},{"name":"National Institute of General Medical Sciences of the National Institutes of Health","award":["P30GM131959"],"award-info":[{"award-number":["P30GM131959"]}]},{"award":["P30GM131959"],"award-info":[{"award-number":["P30GM131959"]}],"id":[{"id":"https:\/\/ror.org\/04q48ey07","id-type":"ROR","asserted-by":"publisher"}]},{"name":"College of Engineering, Computing, and Applied Sciences\u2019 Undergraduate Opportunity Research Grant program"},{"name":"Clemson University Honors College"},{"id":[{"id":"https:\/\/ror.org\/037s24f05","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Clemson Creative Inquiry"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: RNA interference (RNAi) represents a promising therapeutic approach for silencing oncogenes involved in cancer progression by utilizing small interfering RNA (siRNA). However, siRNA requires an efficient delivery system to overcome cellular uptake and endosomal escape barriers. This study aimed to evaluate a multifunctional tandem peptide, GE11-599, designed to enhance the targeted delivery of siRNA and maintain its bioactivity in glioblastoma (GBM) cells. Methods: The GE11-599 peptide, consisting of an EGFR-targeting GE11 motif and a 599 fusogenic domain, was complexed with siRNA via electrostatic interactions to form nanoparticles. We assessed nanoparticle physicochemical properties, protection of siRNA from serum and RNase degradation, and cellular uptake in two GBM cell lines (U118MG and U87MG). Mechanistic studies evaluated receptor-mediated endocytosis and the subsequent escape from endosomes. Functional assays quantified STAT3 gene silencing and downstream effects on cell migration following treatment with GE11-599\u2013siSTAT3 complexes. Results: GE11-599 formed positively charged, monodisperse nanoparticles capable of protecting siRNA from degradation. The tandem peptide significantly enhanced cellular internalization through EGFR-mediated endocytosis and facilitated endosomal escape of siRNA. Treatment with GE11-599\u2013siSTAT3 resulted in robust gene silencing, achieving up to an 80% reduction in STAT3 mRNA expression. Downstream functional assessment showed a 40% decrease in migration in GBM cells treated with GE11-599\u2013siSTAT3 complexes. Conclusions: The GE11-599 tandem peptide effectively enhances cell-specific internalization and endosomal escape of siRNA in GBM cells, resulting in increased siRNA bioactivity and functional gene silencing. These findings support GE11-599 as a promising siRNA delivery platform for targeting EGFR-expressing cancers.<\/jats:p>","DOI":"10.3390\/pharmaceutics18091086","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T18:33:52Z","timestamp":1787942032000},"page":"1086","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["An EGFR-Targeted Fusogenic Tandem Peptide for siRNA Delivery in Glioblastoma"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-3266","authenticated-orcid":false,"given":"Jessica R.","family":"Boulos","sequence":"first","affiliation":[{"name":"Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Karen E.","family":"Russi","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Jordan","family":"Kinnitt","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Daphne","family":"Gomez Escudero","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5360-0597","authenticated-orcid":false,"given":"Tyler","family":"Willis","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"given":"Jorrian","family":"Abadeer","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Emalee","family":"Mann","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Aaron Cristina","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"investigation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"given":"Angela","family":"Alexander-Bryant","sequence":"additional","affiliation":[{"name":"Department of Bioengineering, Nanobiotechnology Laboratory, Clemson University, Clemson, SC 29631, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"methodology","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: Overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","article-title":"Survival in glioblastoma: A review on the impact of treatment modalities","volume":"18","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"ref_3","first-page":"2613","article-title":"Survival analysis of Glioblastoma Multiforme","volume":"19","author":"Witthayanuwat","year":"2018","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"538","DOI":"10.3390\/cancers7020538","article-title":"Glioblastoma: Molecular pathways, stem cells and therapeutic targets","volume":"7","author":"Labagnara","year":"2015","journal-title":"Cancers"},{"key":"ref_5","first-page":"313","article-title":"RNA interference and its role in cancer therapy","volume":"4","author":"Mansoori","year":"2014","journal-title":"Adv. Pharm. Bull."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1146\/annurev-biophys-083012-130404","article-title":"Molecular mechanisms of RNA interference","volume":"42","author":"Wilson","year":"2013","journal-title":"Annu. Rev. Biophys."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sajid, M.I., Moazzam, M., Kato, S., Cho, K.Y., and Tiwari, R.K. (2020). Overcoming barriers for siRNA therapeutics: From bench to bedside. Pharmaceuticals, 13.","DOI":"10.3390\/ph13100294"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"100248","DOI":"10.1016\/j.mtbio.2022.100248","article-title":"Peptide-based delivery of therapeutics in cancer treatment","volume":"14","author":"Samec","year":"2022","journal-title":"Mater. Today Bio"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.colsurfb.2017.07.012","article-title":"Cell targeting peptides as smart ligands for targeting of therapeutic or diagnostic agents: A systematic review","volume":"158","author":"Mousavizadeh","year":"2017","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1021\/nn4057269","article-title":"Cell-penetrating peptides: Design, synthesis, and applications","volume":"8","author":"Copolovici","year":"2014","journal-title":"ACS Nano"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2006.11.050","article-title":"Fusogenic peptides enhance endosomal escape improving siRNA-induced silencing of oncogenes","volume":"331","author":"Oliveira","year":"2007","journal-title":"Int. J. Pharm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19994","DOI":"10.1073\/pnas.1213801109","article-title":"pH-triggered, activated-state conformations of the influenza hemagglutinin fusion peptide revealed by NMR","volume":"109","author":"Lorieau","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"102506","DOI":"10.1016\/j.cbpa.2024.102506","article-title":"Strategies and mechanisms for endosomal escape of therapeutic nucleic acids","volume":"81","author":"Grau","year":"2024","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/jnc.14538","article-title":"Epidermal growth factor receptor and ligand family expression and activity in glioblastoma","volume":"147","author":"Weller","year":"2018","journal-title":"J. Neurochem."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1096\/fj.05-4058com","article-title":"Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics","volume":"19","author":"Li","year":"2005","journal-title":"FASEB J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"534870","DOI":"10.1155\/2021\/5534870","article-title":"GE11 peptide conjugated liposomes for EGFR-targeted and chemophotothermal combined anticancer therapy","volume":"2021","author":"Huang","year":"2021","journal-title":"Bioinorg. Chem. Appl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12032-015-0624-9","article-title":"Peptide GE11\u2013Polyethylene Glycol\u2013Polyethylenimine for targeted gene delivery in laryngeal cancer","volume":"32","author":"Ren","year":"2015","journal-title":"Med. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1021\/acs.molpharmaceut.8b00024","article-title":"GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment","volume":"15","author":"Zou","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Cantini, L., Attaway, C.C., Butler, B., Andino, L.M., Sokolosky, M.L., and Jakymiw, A. (2013). Fusogenic-Oligoarginine Peptide-Mediated Delivery of siRNAs Targeting the CIP2A Oncogene into Oral Cancer Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0073348"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.oraloncology.2017.07.004","article-title":"Dual peptide-mediated targeted delivery of bioactive siRNAs to oral cancer cells in vivo","volume":"72","author":"Zhang","year":"2017","journal-title":"Oral Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.chembiol.2014.11.009","article-title":"Attachment of cell-binding ligands to arginine-rich cell-penetrating peptides enables cytosolic translocation of complexed siRNA","volume":"22","author":"Zeller","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"415","DOI":"10.5483\/BMBRep.2019.52.7.152","article-title":"Highlighted STAT3 as a potential drug target for cancer therapy","volume":"52","author":"Lee","year":"2019","journal-title":"BMB Rep."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Piperi, C., Papavassiliou, K.A., and Papavassiliou, A.G. (2019). Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells, 8.","DOI":"10.3390\/cells8111398"},{"key":"ref_24","unstructured":"Rasband, W. (2026, May 01). ImageJ Version 1.54t, Available online: https:\/\/imagej.net\/ij\/."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0959-8049(01)00233-7","article-title":"The EGFR as a target for anticancer therapy\u2014Focus on cetuximab","volume":"37","author":"Baselga","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"156249","DOI":"10.1016\/j.cyto.2023.156249","article-title":"Engineered CD8+ T cell-derived extracellular vesicles induce enhanced anti-cancer efficacy and targeting to lung cancer cells","volume":"169","author":"Cho","year":"2023","journal-title":"Cytokine"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Fu, W., Hou, X., Dong, L., and Hou, W. (2023). Roles of STAT3 in the pathogenesis and treatment of glioblastoma. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1098482"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Ebenezer, O., Oyebamiji, A.K., Olanlokun, J.O., Tuszynski, J.A., and Wong, G.K.S. (2025). Recent Update on siRNA Therapeutics. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26083456"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1089\/nat.2018.0736","article-title":"GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics","volume":"28","author":"Springer","year":"2018","journal-title":"Nucleic Acid Ther."},{"key":"ref_30","first-page":"1","article-title":"Bioengineering strategies for designing targeted cancer therapies","volume":"118","author":"Wen","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"105663","DOI":"10.1016\/j.jddst.2024.105663","article-title":"\u03b1v\u03b23 integrin targeting RGD peptide-based nanoparticles as an effective strategy for selective drug delivery to tumor microenvironment","volume":"96","author":"Kesharwani","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1021\/acsptsci.3c00280","article-title":"Enhancing RNA Payload and Temperature Stability and Activity with Cationic Peptide-Coated Zinc Oxide Nanoparticles","volume":"7","author":"DeLong","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biochi.2024.01.006","article-title":"Cell-penetrating peptide and cationic liposomes mediated siRNA delivery to arrest growth of chronic myeloid leukemia cells in vitro","volume":"221","author":"Vysochinskaya","year":"2024","journal-title":"Biochimie"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Wang, Y., Zhang, L., Liu, C., Luo, Y., and Chen, D. (2024). Peptide-Mediated Nanocarriers for Targeted Drug Delivery: Developments and Strategies. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020240"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Liu, M., Fang, X., Yang, Y., and Wang, C. (2021). Peptide-Enabled Targeted Delivery Systems for Therapeutic Applications. Front. Bioeng. Biotechnol., 9.","DOI":"10.3389\/fbioe.2021.701504"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.3390\/chemistry5030116","article-title":"Peptide-Based Vectors for Gene Delivery","volume":"5","author":"Yang","year":"2023","journal-title":"Chemistry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"8620","DOI":"10.1021\/nn301975s","article-title":"Identification and characterization of receptor-specific peptides for siRNA delivery","volume":"6","author":"Ren","year":"2012","journal-title":"ACS Nano"},{"key":"ref_38","first-page":"147ra112","article-title":"Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4","volume":"4","author":"Ren","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_39","first-page":"444","article-title":"Size, shape, charge and \u2018stealthy\u2019 surface: Carrier properties affect the drug circulation time in vivo","volume":"16","author":"Di","year":"2021","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"106167","DOI":"10.1016\/j.jddst.2024.106167","article-title":"Tuning the surface charge and colloidal stability of hybrid gold-chitosan derivative nanoparticles for siRNA delivery","volume":"101","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1007\/s12274-017-1918-3","article-title":"Surface charge tunable nanoparticles for TNF-\u03b1 siRNA oral delivery for treating ulcerative colitis","volume":"11","author":"Iqbal","year":"2018","journal-title":"Nano Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12951-021-00791-x","article-title":"Novel fusion peptide-mediated siRNA delivery using self-assembled nanocomplex","volume":"19","author":"Ryu","year":"2021","journal-title":"J. Nanobiotechnology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2011.07.100","article-title":"Epidermal growth factor receptors destined for the nucleus are internalized via a clathrin-dependent pathway","volume":"412","author":"Rodrigues","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.bbrc.2010.07.096","article-title":"COPI-mediated retrograde trafficking from the Golgi to the ER regulates EGFR nuclear transport","volume":"399","author":"Wang","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"10502","DOI":"10.1021\/nn4033294","article-title":"Epidermal growth factor receptor targeted nuclear delivery and high-resolution whole cell x-ray imaging of Fe3O4@TiO2 nanoparticles in cancer cells","volume":"7","author":"Yuan","year":"2013","journal-title":"ACS Nano"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"216920","DOI":"10.1016\/j.canlet.2024.216920","article-title":"A natural compound melatonin enhances the effects of Nimotuzumab via inhibiting EGFR in glioblastoma","volume":"592","author":"Wang","year":"2024","journal-title":"Cancer Lett."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3892\/or.2024.8813","article-title":"Engineered extracellular vesicles with polypeptide for targeted delivery of doxorubicin against EGFR-positive tumors","volume":"52","author":"Yang","year":"2024","journal-title":"Oncol. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e3558","DOI":"10.1002\/psc.3558","article-title":"Hydrophobicity: The door to drug delivery","volume":"30","author":"Falanga","year":"2024","journal-title":"J. Pept. Sci."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Uribe, M.L., Marrocco, I., and Yarden, Y. (2021). EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance. Cancers, 13.","DOI":"10.3390\/cancers13112748"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"121134","DOI":"10.1016\/j.ijpharm.2021.121134","article-title":"Active targeting strategy in nanomedicines using anti-EGFR ligands\u2014A promising approach for cancer therapy and diagnosis","volume":"609","author":"Nguyen","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"120082","DOI":"10.1016\/j.ijpharm.2020.120082","article-title":"EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles","volume":"592","author":"Santos","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Rodriguez, S.M.B., Kamel, A., Ciubotaru, G.V., Onose, G., Sevastre, A.-S., Sfredel, V., Danoiu, S., Dricu, A., and Tataranu, L.G. (2023). An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241311110"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Barcan, E.N., Duta, C., Staicu, G.A., Artene, S.A., Alexandru, O., Costachi, A., Pirvu, A.S., Tache, D.E., Stoian, I., and Popescu, S.O. (2025). Current Research Trends in Glioblastoma: Focus on Receptor Tyrosine Kinases. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202501.2317.v1"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Genta, I., Chiesa, E., Colzani, B., Modena, T., Conti, B., and Dorati, R. (2018). GE11 peptide as an active targeting agent in antitumor therapy: A minireview. Pharmaceutics, 10.","DOI":"10.3390\/pharmaceutics10010002"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.omtn.2021.03.013","article-title":"Advancing peptide siRNA-carrier designs through L\/D-amino acid stereochemical modifications to enhance gene silencing","volume":"24","author":"Holjencin","year":"2021","journal-title":"Mol. Ther.-Nucleic Acids"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3697","DOI":"10.2147\/IJN.S498629","article-title":"Early Detection of Brain Metastases from Triple-Negative Breast Cancer with a Tumor-Targeting Dual-Modal MR\/NIRF Imaging Probe","volume":"20","author":"Nie","year":"2025","journal-title":"Int. J. Nanomed."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e2307800120","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: A bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"115047","DOI":"10.1016\/j.addr.2023.115047","article-title":"Get out or die trying: Peptide- and protein-based endosomal escape of RNA therapeutics","volume":"200","author":"Klipp","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jconrel.2015.09.026","article-title":"Fusogenic-oligoarginine peptide-mediated silencing of the CIP2A oncogene suppresses oral cancer tumor growth in vivo","volume":"218","author":"Dumitriu","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1021\/acs.accounts.9b00177","article-title":"Carriers break barriers in drug delivery: Endocytosis and endosomal escape of gene delivery vectors","volume":"52","author":"Degors","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1261\/rna.079507.122","article-title":"Endosomal escape of RNA therapeutics: How do we solve this rate-limiting problem?","volume":"29","author":"Dowdy","year":"2023","journal-title":"RNA"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"421821","DOI":"10.1155\/2013\/421821","article-title":"Role of STAT3 in cancer metastasis and translational advances","volume":"2013","author":"Kamran","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/cancers6010376","article-title":"STAT3 activation in glioblastoma: Biochemical and therapeutic implications","volume":"6","author":"Kim","year":"2014","journal-title":"Cancers"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12935-025-03770-6","article-title":"STAT3\/TGFBI signaling promotes the temozolomide resistance of glioblastoma through upregulating glycolysis by inducing cellular senescence","volume":"25","author":"Zhang","year":"2025","journal-title":"Cancer Cell Int."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1158\/1535-7163.MCT-11-0801","article-title":"STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression","volume":"11","author":"Kohsaka","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.omtn.2017.12.021","article-title":"STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma","volume":"10","author":"Esposito","year":"2018","journal-title":"Mol. Ther.-Nucleic Acids"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1086\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T04:29:29Z","timestamp":1788064169000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/9\/1086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,28]]},"references-count":66,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["pharmaceutics18091086"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18091086","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,28]]}}}